Beijing King Health Investment

The main purpose of the study was to compare the pharmacokinetics of olanzapine orodisintegrating tablets (specification: 5 mg/tablet, test preparation) imported by Beijing Jinkangchi Pharmaceutical Investment Co., Ltd. and olanzapine orodisintegrating tablets (specification: 5 mg/tablet, trade name: Zyprexa, reference preparation) from the licensed manufacturer Eli Lilly Nederland B.V. in healthy subjects, and to evaluate the bioequivalence of the two preparations taken orally in the fed state. The secondary purpose of the study was to observe the safety of the test preparation olanzapine orodisintegrating tablets 5 mg and the reference preparation Zyprexa 5 mg in healthy subjects.